Programing Assembling/Releasing Multifunctional miRNA Nanomedicine to Treat Prostate Cancer.
Ding MaHongmei LiuPeipei ZhaoLi YeHanbing ZouXue ZhaoHuili DaiXianming KongPeifeng LiuPublished in: ACS applied materials & interfaces (2020)
MicroRNAs (miRNAs) therapy has shown to have great promise for the treatment of androgen-independent prostate cancer (AIPC) due to the low efficiency of hormonal therapy. However, instability of RNA and inefficiency of RNA therapy limit the use of miRNAs in the treatment of AIPC. Here, we report a pH/ATP-activated nanocomplexes for increasing cytosolic delivery of miR146a which can effectively inhibit the expression of epidermal growth factor receptor (EGFR) in AIPC. The nanocomplexes show identical suppressing effect in invasion, colony formation, migration ability, and growth of DU145 cells compared with Lipofectamine 2000 (lipo). But for in vivo experiments, the nanocomplexes vigorously suppress the growth of tumor volumes comparing to lipo group after five weeks' treatment. These results demonstrate the potential of the pH/ATP-activated nanocarriers for AIPC gene therapy.
Keyphrases
- prostate cancer
- epidermal growth factor receptor
- gene therapy
- tyrosine kinase
- drug delivery
- radical prostatectomy
- advanced non small cell lung cancer
- cell proliferation
- signaling pathway
- metabolic syndrome
- insulin resistance
- stem cells
- big data
- cell death
- machine learning
- bone marrow
- skeletal muscle
- deep learning
- binding protein
- endoplasmic reticulum stress
- climate change
- preterm birth
- pi k akt
- cell migration